ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 914.6 USD | +1.83% |
|
+1.02% | +56.89% |
| 10:36am | Eli Lilly, Novo Holdings Participate in Myricx Bio's $114 Million Financing Round | MT |
| Jul. 04 | ETF of the week: Investing in strong trends with the momentum theme |  |
Financials (USD)
| Sales 2024 * | 42.97B | Sales 2025 * | 52.69B | Capitalization | 823B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B | Net income 2025 * | 16.63B | EV / Sales 2024 * | 19.6 x |
| Net Debt 2024 * | 19.94B | Net Debt 2025 * | 16.06B | EV / Sales 2025 * | 15.9 x |
| P/E ratio 2024 * |
68.4
x | P/E ratio 2025 * |
49
x | Employees | 43,000 |
| Yield 2024 * |
0.57% | Yield 2025 * |
0.66% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +1.83% | ||
| 1 week | +1.02% | ||
| Current month | +1.02% | ||
| 1 month | +7.60% | ||
| 3 months | +16.62% | ||
| 6 months | +47.86% | ||
| Current year | +56.89% |
1 week
878.50
918.50
1 month
849.39918.50
Current year
579.05918.50
1 year
434.34918.50
3 years
220.20918.50
5 years
101.36918.50
10 years
60.14918.50
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 21 M€ | +10.60% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 914.6 | +1.83% | 2,880,863 |
| 24-07-03 | 898.1 | -0.95% | 3,078,367 |
| 24-07-02 | 906.7 | -0.84% | 4,584,602 |
| 24-07-01 | 914.4 | +0.99% | 2,546,119 |
Delayed Quote Nyse, July 05, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.89% | 823B | |
| +40.47% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +14.04% | 239B | |
| +14.37% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- LLY Stock
